IS8438A - Setin tríasól sem natríum gangahemla - Google Patents
Setin tríasól sem natríum gangahemlaInfo
- Publication number
- IS8438A IS8438A IS8438A IS8438A IS8438A IS 8438 A IS8438 A IS 8438A IS 8438 A IS8438 A IS 8438A IS 8438 A IS8438 A IS 8438A IS 8438 A IS8438 A IS 8438A
- Authority
- IS
- Iceland
- Prior art keywords
- pain
- alone
- pharmaceutically acceptable
- effective amount
- compounds
- Prior art date
Links
- 229940123268 Sodium antagonist Drugs 0.000 title 1
- 150000003852 triazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 208000002193 Pain Diseases 0.000 abstract 3
- 208000020925 Bipolar disease Diseases 0.000 abstract 2
- 208000019695 Migraine disease Diseases 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010027599 migraine Diseases 0.000 abstract 2
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 238000002690 local anesthesia Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- -1 triazole compounds Chemical class 0.000 abstract 1
- 208000009935 visceral pain Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51889003P | 2003-11-10 | 2003-11-10 | |
| PCT/US2004/037280 WO2005047270A2 (en) | 2003-11-10 | 2004-11-05 | Substituted triazoles as sodium channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS8438A true IS8438A (is) | 2006-05-04 |
Family
ID=34590316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8438A IS8438A (is) | 2003-11-10 | 2006-05-04 | Setin tríasól sem natríum gangahemla |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20090074890A1 (enExample) |
| EP (1) | EP1694654B1 (enExample) |
| JP (1) | JP2007510741A (enExample) |
| KR (1) | KR20060123739A (enExample) |
| CN (1) | CN1922156A (enExample) |
| AT (1) | ATE500234T1 (enExample) |
| AU (1) | AU2004289694B2 (enExample) |
| BR (1) | BRPI0416319A (enExample) |
| CA (1) | CA2545254A1 (enExample) |
| DE (1) | DE602004031667D1 (enExample) |
| IL (1) | IL175522A0 (enExample) |
| IS (1) | IS8438A (enExample) |
| NO (1) | NO20062676L (enExample) |
| NZ (1) | NZ547044A (enExample) |
| RU (1) | RU2372339C2 (enExample) |
| WO (1) | WO2005047270A2 (enExample) |
| ZA (1) | ZA200603583B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY142651A (en) * | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| US20090074890A1 (en) * | 2003-11-10 | 2009-03-19 | Park Min K | Substituted Triazoles as Sodium Channel Blockers |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0603008D0 (en) * | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
| KR100808551B1 (ko) | 2006-12-01 | 2008-03-03 | 한국생명공학연구원 | 트리아졸 유도체를 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| MX2009008547A (es) | 2007-02-08 | 2010-01-15 | Synta Pharmaceuticals Corp | Compuestos de triazol que son utiles en el tratamiento de trastornos proliferativos tales como cancer. |
| ES2398854T3 (es) * | 2007-04-03 | 2013-03-22 | E. I. Du Pont De Nemours And Company | Fungicidas de benceno sustituido |
| AU2008316708A1 (en) * | 2007-10-25 | 2009-04-30 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
| MX2010004563A (es) * | 2007-10-25 | 2010-07-28 | Revalesio Corp | Composiciones y métodos para modular la transducción de la señal intracelular mediada por la membrana celular. |
| EP2222638A2 (en) * | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating inflammation |
| EP2222639A1 (en) | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| EP2531510B1 (en) | 2010-02-01 | 2014-07-23 | Novartis AG | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
| US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
| CN104271579A (zh) | 2012-05-03 | 2015-01-07 | 诺华股份有限公司 | 作为生长素释放肽受体激动剂的2,7-二氮杂-螺[4,5]癸烷-7-基衍生物的l-苹果酸盐及其结晶 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3682075B2 (ja) * | 1993-04-16 | 2005-08-10 | クミアイ化学工業株式会社 | トリアゾール誘導体及び殺虫、殺ダニ剤 |
| TW533205B (en) * | 1996-06-25 | 2003-05-21 | Novartis Ag | Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition |
| IT1300055B1 (it) * | 1998-04-17 | 2000-04-05 | Boehringer Ingelheim Italia | Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici |
| AR029489A1 (es) * | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
| WO2001072714A2 (en) * | 2000-03-24 | 2001-10-04 | Euro-Celtique S.A. | Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker |
| AR037233A1 (es) * | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| MY142651A (en) * | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| US20060183897A1 (en) * | 2003-03-18 | 2006-08-17 | Chakravarty Prasun K | Biaryl substituted triazoles as sodium channel blockers |
| US20090074890A1 (en) * | 2003-11-10 | 2009-03-19 | Park Min K | Substituted Triazoles as Sodium Channel Blockers |
-
2004
- 2004-11-05 US US10/578,950 patent/US20090074890A1/en not_active Abandoned
- 2004-11-05 AT AT04800897T patent/ATE500234T1/de not_active IP Right Cessation
- 2004-11-05 NZ NZ547044A patent/NZ547044A/en unknown
- 2004-11-05 EP EP04800897A patent/EP1694654B1/en not_active Expired - Lifetime
- 2004-11-05 AU AU2004289694A patent/AU2004289694B2/en not_active Ceased
- 2004-11-05 BR BRPI0416319-2A patent/BRPI0416319A/pt not_active Application Discontinuation
- 2004-11-05 CA CA002545254A patent/CA2545254A1/en not_active Abandoned
- 2004-11-05 CN CNA2004800329352A patent/CN1922156A/zh active Pending
- 2004-11-05 RU RU2006120426/04A patent/RU2372339C2/ru not_active IP Right Cessation
- 2004-11-05 KR KR1020067009120A patent/KR20060123739A/ko not_active Ceased
- 2004-11-05 JP JP2006539729A patent/JP2007510741A/ja not_active Ceased
- 2004-11-05 DE DE602004031667T patent/DE602004031667D1/de not_active Expired - Lifetime
- 2004-11-05 WO PCT/US2004/037280 patent/WO2005047270A2/en not_active Ceased
- 2004-11-10 US US10/985,592 patent/US7459475B2/en not_active Expired - Lifetime
-
2006
- 2006-05-04 IS IS8438A patent/IS8438A/is unknown
- 2006-05-05 ZA ZA200603583A patent/ZA200603583B/xx unknown
- 2006-05-09 IL IL175522A patent/IL175522A0/en unknown
- 2006-06-09 NO NO20062676A patent/NO20062676L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1922156A (zh) | 2007-02-28 |
| AU2004289694A1 (en) | 2005-05-26 |
| DE602004031667D1 (de) | 2011-04-14 |
| ZA200603583B (en) | 2007-08-29 |
| US7459475B2 (en) | 2008-12-02 |
| EP1694654B1 (en) | 2011-03-02 |
| JP2007510741A (ja) | 2007-04-26 |
| NZ547044A (en) | 2010-05-28 |
| WO2005047270A2 (en) | 2005-05-26 |
| US20060020006A1 (en) | 2006-01-26 |
| IL175522A0 (en) | 2006-09-05 |
| BRPI0416319A (pt) | 2007-01-09 |
| RU2006120426A (ru) | 2007-12-27 |
| KR20060123739A (ko) | 2006-12-04 |
| US20090074890A1 (en) | 2009-03-19 |
| RU2372339C2 (ru) | 2009-11-10 |
| NO20062676L (no) | 2006-08-10 |
| CA2545254A1 (en) | 2005-05-26 |
| WO2005047270A3 (en) | 2005-09-22 |
| ATE500234T1 (de) | 2011-03-15 |
| AU2004289694B2 (en) | 2010-05-13 |
| EP1694654A2 (en) | 2006-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO2480B1 (en) | Triple aryl substituted with aryl as a sodium channel blocking agent | |
| IS8438A (is) | Setin tríasól sem natríum gangahemla | |
| MX2009004475A (es) | Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma. | |
| WO2004084824A3 (en) | Biaryl substituted 6-membered heterocyles as sodium channel blockers | |
| WO2007145922A3 (en) | Benzazepinones as sodium channel blockers | |
| MX2025001995A (es) | Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo | |
| MXPA05010185A (es) | Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk. | |
| DK0766672T3 (da) | Arylsulfonamido-substituerede hydroxamsyrer som matrixmetallopreteinase-inhibitorer | |
| WO2007075524A3 (en) | Substituted piperidines as calcium channel blockers | |
| WO2005030766A8 (en) | Phenyl - carboxamide compounds useful for treating pain | |
| MY150682A (en) | Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival | |
| GEP20125389B (en) | Substituted pyrazole and triazole compounds as ksp inhibitors | |
| EA201071395A1 (ru) | Ингибитор толерантности к анальгетику | |
| MXPA05013151A (es) | 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b. | |
| PH12022552495A1 (en) | Oxazolidinone compound and methods of use thereof as an antibacterial agent | |
| TW200800951A (en) | Substituted imidazole compounds as KSP inhibitors | |
| GEP20257771B (en) | Compounds and compositions as sppl2a inhibitors | |
| WO2006009893A3 (en) | Cancer chemotherapy | |
| MXPA05008711A (es) | Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico. | |
| MX2023011554A (es) | Composicion farmaceutica para la prevencion o tratamiento de enfermedad inflamatoria intestinal que actua como un antagonista funcional para s1pr1 y s1pr4. | |
| WO2007047881A3 (en) | Method for treating neuropathic pain | |
| MX2024002892A (es) | Azalidos inmunomoduladores. | |
| MX2023009620A (es) | Metodos terapeuticos. | |
| NZ789014A (en) | Sphingosine-1-phosphate receptor agonist, preparation method therefor, and pharmaceutical composition containing same as active ingredient | |
| MX2024014168A (es) | Antagonistas de at2r y usos de estos |